Amphastar Pharmaceuticals AMPH Pharmaceutical Products — Interest Expense Nonoperating

Similar metrics at other companies

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Interest Expense, Nonoperating

$1.75M+101%

CVIPetroleum Segment — Interest Expense, Nonoperating

$4M-42.9%

PTCTLife Science — Interest Expense Nonoperating

$67.02M+30.5%

CVCOFinancial services — Interest Expense, Nonoperating

$0—

CAPRInterest Expense, Nonoperating

$761.43K—

NHCInpatient Services — Interest Expense Nonoperating

$269K-87.2%

Questions, answered.

What is Amphastar Pharmaceuticals's pharmaceutical products — interest expense nonoperating?

Amphastar Pharmaceuticals (AMPH) reported pharmaceutical products — interest expense nonoperating of $6.55M in Q1 2026.

How has Amphastar Pharmaceuticals's pharmaceutical products — interest expense nonoperating changed year-over-year?

Amphastar Pharmaceuticals's pharmaceutical products — interest expense nonoperating increased by 4.2% year-over-year, from $6.29M to $6.55M.

What does pharmaceutical products — interest expense nonoperating mean?

This metric captures the non-operating interest costs associated with debt or financing arrangements specifically attributed to the pharmaceutical products segment. It reflects the cost of capital utilized to fund segment-specific operations, acquisitions, or infrastructure. High levels of this expense relative to segment earnings may indicate increased financial leverage and risk.